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Rapidly evolving genome technology has enabled extensive molecular analysis of limited tumor
biopsy material, thereby facilitating the broader implementation of personalized cancer medicine.
However, genomics-based patient stratification across diverse tumor types is unlikely to supplant
tissue-of-origin considerations in addressing clinical needs, including the development and appli-
cation of novel ‘‘rationally targeted’’ cancer therapies.Discovery and translational research con-
ducted during the past 30 years has led
to the identification and validation of a
number of ‘‘cancer drivers’’—genes that,
when mutated or otherwise dysregulated,
can drive malignancy in model systems.
Several treatments that directly target
such drivers have yielded unprecedented
activity in early-stage clinical trials, result-
ing in relatively rapid regulatory approval.
These approvals have typically refer-
enced diagnostic tests performed on
tumor tissue to indicate the presence of
a biomarker that predicts response. Thus,
for example, the HER2-targeted antibody
trastuzumab is approved for use in breast
cancer patients whose tumors exhibit
overexpression of HER2 as demonstrated
by fluorescence in situ hybridization
(FISH) or immunohistochemistry (Fig-
ueroa-Magalhaes et al., 2013). A more
recent example is the BRAF kinase inhib-
itor vemurafenib, which is approved for
treatment of metastatic melanomas that
harbor a particular activating BRAFmuta-
tion in the tumor DNA (Chapman et al.,
2011), and there are now additional exam-
ples of successful clinical implementation
of biomarker-guided cancer treatments—
particularly with inhibitors of the various
oncogenic kinases. Consequently, the
number of patients for whom such
genomic information is available at some
point in their disease course is rapidly
increasing.
Technologies for genomic profiling of
tumors have rapidly evolved over the
past decade. Early efforts to profile tumorDNA involved single-nucleotide polymor-
phism (SNP) mapping and comparative
genomic hybridization (CGH) to describe
segmental gains or losses of DNA, as
well as rearrangements. More recently,
genomic analysis has focused on muta-
tion identification via resequencing of
either a limited set of genes, whole
exomes, or whole genomes. In addition,
advances in RNA-based technologies,
including improved expression arrays
and RNA sequencing, have provided
more accurate gene expression profiles
that have proven particularly useful for
tumor classification and prognostica-
tion in several anatomic sites and for
tissue-of-origin assessment in cases of
carcinomas of unknown primary origin
(Monzon et al., 2009). Efforts to profile
the tumor ‘‘epigenome’’ have also been
intensifying. A variety of genome-wide
assessments of DNAmethylation, histone
modification, and transcription factor
occupancy on DNA have now been
described, though none have been widely
used clinically thus far.
In considering the case for genomics-
based patient stratification in the follow-
ing discussion, our goal is to address the
question of whether tissue-of-origin-
based classification is likely to remain
relevant in the face of an increasingly
‘‘genome-centric’’ view of human tumors.
We see two key considerations. First, how
can patient-specific genomic profiling
be optimally used to guide clinical care
and thus realize the vision of ‘‘preci-
sion oncology’’ (Garraway et al., 2013)?Cell 15Second, should tumors still be classified
on the basis of tissue-of-origin, or
should revamped classification based on
genomic features be substituted? In the
analysis and recommendations that
follow, we consider the lessons learned
from the initial wave of ‘‘rationally tar-
geted’’ therapies in light of current trends.
We offer a perspective on the emerging
use of tumor genome information to
accelerate the clinical development of
novel agents and to optimize the use of
current therapeutics.
Early oncogene discovery efforts were
largely focused on identifying dominantly
acting, mutated genes that are capable
of transforming cells to a malignant state
as ameans of elucidating potential cancer
drivers. Transformation assays that were,
in retrospect, extremely sensitive to
mutationally activated Ras and various
signal-transducing kinases, for example,
quickly revealed that activating onco-
genic mutations are relatively common
in human cancers and implicated the
corresponding oncoproteins as targets
for rational therapy. Perhaps the most
compelling clinical data resulting from
such work was the demonstration in
phase I studies that the ABL kinase inhib-
itor imatinib exhibited unprecedented
activity in advanced cases of chronic
myelogenous leukemia (CML), a disease
in which virtually every case is character-
ized by an oncogenic rearrangement
of the Abl gene (Druker et al., 2001a,
2001b). The imatinib experience in CML
proved the principle that remarkable7, June 19, 2014 ª2014 Elsevier Inc. 1509
clinical benefit could be achieved by
directly targeting mutationally activated
oncoproteins. Similar subsequent experi-
ence with other targeted agents further
supported this paradigm—as exemplified
by the dramatic activity of EGFR and ALK
kinase inhibitors in EGFR mutant and
ALK-rearranged lung cancers, respec-
tively (Minuti et al., 2013).
The feasibility of genomically guided
clinical trial design is now well estab-
lished. In several tumor types, oncogenic
mutations have been reliably identified
by sequencing tumor-derived DNA,
and mutation-positive patients have
been subsequently evaluated for their
response to targeted agents in clinical
trials. For example, the EURTAC study
of the EGFR inhibitor erlotinib as initial
treatment enrolled patients with EGFR
mutant metastatic lung cancer. Gratify-
ingly, the study was positive at an early
interim evaluation point (Rosell et al.,
2012). Randomization was stopped after
only 174 patients were enrolled when
interim data revealed that patients
treated with erlotinib lived twice as long
without disease progression compared
to those treated with chemotherapy.
These dramatic results were obtained
more than 5 years after erlotinib’s initial1510 Cell 157, June 19, 2014 ª2014 Elsevierapproval for non-small cell lung cancer,
which was granted without regard
to EGFR status. In that pivotal study,
more than 700 patients were random-
ized, and the effect on progression-
free survival was much more modest
(2.2 months versus 1.8 months with
chemotherapy). Clearly, genomic infor-
mation can be useful in guiding the suc-
cessful development of novel targeted
agents.
Clinical researchers have come to
expect ‘‘breakthrough efficacy’’ as the
hallmark of an agent effectively targeting
a tumor driver. Indeed, revisions to clinical
trial methodology to facilitate early
approval of particularly active agents
have been proposed by a number of
groups, including patient advocacy orga-
nizations (Horning et al., 2013; Mullins
et al., 2012). Moreover, the relatively
recently acquired ability to collect whole-
genome expression profiles and deep
DNA sequence information from small
amounts of tumor biopsy material has
provided an opportunity to greatly expand
the use of molecular profiling in guiding
drug development and treatment deci-
sions. However, as described below,
additional context is required to make
optimal use of this information.Inc.Paralleling these key discoveries sup-
porting the ‘‘oncogene addiction’’ para-
digm and the consequent potential for
personalizing cancer drug therapy, in-
creasingly comprehensive tumor genome
analysis has revealed that similar acti-
vating mutations are present in tumors
derived from different tissue types, point-
ing to potential common therapeutic
vulnerabilities among tumors of distinct
origin. Results of early attempts to gener-
alize the use of targeted agents across
histologically distinct cancers following
initial proof of concept in a given tumor
type have been mixed. Recent experi-
ence with BRAF-targeted agents in pa-
tients with the identical activating BRAF
mutation provides a case in point and
suggests that tissue context may indeed
be an important determinant of treatment
response. V600E or similarly activating
BRAF mutations are seen in 5%–8%
of colorectal cancers, 30%–70% of
papillary thyroid tumors, and a smaller
fraction of tumorsderived from lung, brain,
and various other tissues (http://cancer.
sanger.ac.uk/cosmic/gene/analysis?ln=
BRAF#dist). Although vemurafenib is
highly active in the treatment of mela-
nomas harboring the V600E mutation,
clinical studies of vemurafenib in BRAF
mutant colorectal cancer have been
disappointing thus far, and recent findings
implicate EGFR signaling in bypassing
a strict dependency on activated BRAF
in this setting (Corcoran et al., 2012;
Prahallad et al., 2012). The precise role of
BRAF in other settings where it undergoes
mutational activation is even less clear.
The BRAF experience thus far suggests
that relatively low mutation frequencies
across a diverse range of histologic
tumor types will present major obstacles
to the clinical evaluation of targeted
treatments. In addition, tissue context
clearly affects the prognostic impact
of driver mutations, with examples pro-
vided by the variable effects reported
for KRAS, EGFR, and BRAF mutations
among tumors of the lung and colon
(Bauml et al., 2013; Custodio and Feliu,
2013).
Recently, so-called ‘‘basket’’ studies
have been proposed to facilitate the
development of novel targeted anticancer
agents (Willyard, 2013). In this trial
design paradigm, patients with disparate
tumors (derived from distinct tissue
types) are eligible for similar treatment
if their tumor harbors a pre-specified
genetic lesion. Basket designs may be
particularly appealing when either the
genetic lesion or the particular tumor
types (or both) are relatively rare. Howev-
er, grouping patients in this way is
cumbersome and runs the risk of failing
to address practical disease-manage-
ment needs. As an obvious example,
integrated cancer care includes consider-
ation of local therapies in addition to
systemic ones and often involves sur-
geons, oncologists, and radiotherapists
who specialize in a particular tissue type
or organ system.
The challenges for clinical research and
drug development created by the pres-
ence of relatively low-frequency driver
mutations distributed across a variety of
tumor types have prompted consider-
ation of whether genomic analysis of
tumor biopsies should be applied more
broadly or should even replace traditional
histology-based diagnosis of cancer.
The data for BRAF and other oncogenes
suggest that the notion that a ‘‘driver’’
mutation behaves similarly across tumor
contexts may be invalid, yet this is a crit-
ical assumption underlying the rationale
for driver-based classification. We believe
that the biology of each putative driver
must be addressed in specific tissue-
defined disease contexts to establish
a compelling scientific rationale for using
molecular classification as the domi-
nant criterion for patient stratification.
Currently, the focus of pathologic disease
classification remains decidedly on
anatomic tissue of origin. But traditional
pathologic classification can respond
quickly to important new information.
Thus, elucidation of HER2 biology and
the availability of effective anti-HER2
treatments led to the inclusion of ‘‘HER2
positive’’ as an important classification
parameter carrying prognostic informa-
tion as well as offering the potential to
guide treatment (Sauter et al., 2009).
A more elaborate example is provided
by the clinical experience with pre-
cursor B-cell acute lymphoblastic leuke-
mia (B-ALL), the most common childhood
tumor. Over the past 30 years, hemato-
pathologists grappled first with new infor-
mation about cell surface markers on
various leukemias and, more recently,
with cytogenetic, genetic, and epigeneticinformation derived from a large number
of cases. Although histologic assessment
has diminished somewhat in importance,
the result has been a tremendously valu-
able classification scheme based on an
amalgamation of this information (Mul-
lighan, 2012). Currently, 10–12 types of
B-ALL are recognized, with frequencies
ranging from 1%–30%. Classification on
this basis provides predictive information
about the efficacy of high-dose conven-
tional chemotherapy and that of newer
targeted treatments, as well as valuable
prognostic information.
In light of such examples, at present
there seems to be little to be gained
from a substantial effort to reclassify
tumors on the basis of molecular pheno-
type, irrespective of the site of origin.
The effort required for such a conceptual
change would be large and the payoff
uncertain. Variable driver effects across
tumor types would likely limit both the
value and utility of the resulting classifi-
cation system. However, regardless of
the potential need to revise the basis for
pathologic tumor classification, the ratio-
nale for routinely including tumor genomic
analysis as part of a pathology report
seems compelling. The number of tar-
geted investigational agents is increasing
rapidly, and regulatory approval man-
dates the performance of a ‘‘companion’’
diagnostic test in many cases. Conse-
quently, DNA-based diagnostic assays
have begun to be performed routinely in
the clinical pathology setting. It is essen-
tial that such information is provided in
the medical record, given its emerging
value in clinical decision making. As
examples, consider the FDA approvals
of the BRAF inhibitors dabrafenib and
vemurafenib. Both were granted an iden-
tical indication as follows: ‘‘indicated for
the treatment of patients with unresect-
able or metastatic melanoma with BRAF
V600E mutation as detected by an FDA-
approved test.’’ These indication state-
ments frame important issues in the
future development and rational applica-
tion of precision oncologic treatments:
if only a subset of patients is expected
to benefit, how should appropriate pa-
tients be identified? Will regulatory au-
thorities (and, ultimately, payers) continue
to require specific, dedicated diagnostic
tests, i.e., ‘‘companion diagnostics,’’
before a product can be used? Or, willCell 15the easy availability and decreasing cost
of broad-based tumor sequence data
supplant the need for future ‘‘one-off’’
companion diagnostics? Although the
routine clinical generation of ‘‘actionable’’
cancer genomic information is in its rela-
tive infancy, it is clear that pathologists
and clinicians will inevitably need to
confront the implications of a much
more data-rich future.
It is instructive to consider the
emerging experience with tumor se-
quencing for identification of driver muta-
tions in the context of successful classi-
fication systems such as those used in
the leukemias. In leukemia classification,
as mentioned above, a variety of
approaches have proven useful. Cell phe-
notyping by FACS, cytogenetics, and
gene expression profiling can stratify leu-
kemias into robust subgroups manifest-
ing different behaviors across studies.
Upon more detailed genomic profiling,
many of these subgroups demonstrate
an enrichment for specific mutations
and epigenetic patterns (Miller et al.,
2013). These, in turn, demonstrate unique
responses to conventional and targeted
therapies, as well as distinct clinical
behaviors.
It is increasingly critical that future
tumor classification approaches enable
reliable prediction of response to targeted
agents such as kinase inhibitors. As an
example, after demonstrating safety in a
phase 1 clinical study, the multikinase
inhibitor sorafenib was evaluated in a
broad-based phase 2 trial that ultimately
included more than 500 patients (Eisen
et al., 2006). Eventual regulatory approval
in renal cell cancer was based on the
results from a phase 3 study of almost
1,000 patients with nomolecular selection
criteria (Escudier et al., 2007). Another
1,000 patients were studied to gain
subsequent approvals in hepatocellular
carcinoma and thyroid cancer, again
without molecular selection criteria (Iyer
et al., 2010). Although the activity of
sorafenib in certain clinical situations
is unequivocal, the failure to identify
responsive subpopulations in studies
involving more than 2,500 patients is
disappointing for a putative targeted
agent. It is even possible that the clinical
benefit associated with sorafenib treat-
ment reflects an anti-angiogenic activity
resulting from VEGF receptor inhibition,7, June 19, 2014 ª2014 Elsevier Inc. 1511
which would probably not be revealed
through tumor genome analysis (Heng
and Bukowski, 2008).
The recently proposed basket trial
design offers a number of advantages
in surveying potentially responsive tu-
mors, including the opportunity to study
the feasibility of obtaining comprehen-
sive genomic and epigenetic profiles for
all patients. Examples of genetic driver
lesions appropriate for such designs
include the genomic activation of ALK
in some anaplastic lymphomas, neuro-
blastomas, and lung cancers, as well
as the spectrum of BRAF mutant and
PIK3CA (PI3 kinase) mutant tumors,
which have been associated with diverse
tumor types (Eifert and Powers, 2012).
Although regulatory agencies are unlikely
to accept small numbers of patients as
a basis for approval, such studies can
flexibly expand patient numbers in
responsive populations to increase the
confidence in any observed signals. For
relatively rare diseases in which the
need for new treatments is great and
options are limited, such data may be
sufficient to support additional indica-
tions for previously approved agents.
However, basket trials may present sig-
nificant risk in the context of a primary
approval focused on a particular genetic
lesion rather than a given tumor type
because there is no certainty of a
consistent therapeutic effect across
tumor types. Indeed, the net outcome
of such studies could be the ‘‘dilution’’
of an important treatment benefit, as
experience to date suggests that tis-
sue-specific effects are common (Dan-
cey et al., 2012). Thus, the sample size
requirement for basket trials might be
many times larger than a more focused
trial in order to provide sufficient statis-
tical power for informative subgroup
analysis.
Accumulating experience suggests that
comprehensive profiling within a given
tumor type is most likely to provide
a solid basis for useful classification. By
integrating expression, sequence, and
epigenetic information, it is reasonable
to expect that robust subtypes can be
identified, as has been the case for the
leukemias. A particularly acute need is
epigenomic profiling. Previous assays
have been extremely cumbersome and
have produced limited patient-specific1512 Cell 157, June 19, 2014 ª2014 Elsevierinformation. Despite this, both histone
deacetylase inhibitors and DNA-deme-
thylating agents have been approved
for limited indications. However, the
potential utility of such agents in broad
tumor populations is largely unknown.
Simpler sequence-based methods for
epigenetic profiling have recently been
described (Buenrostro et al., 2013), and
such approaches may provide essential
information to help predict the clinical util-
ity of epigenetic modifiers in broader dis-
ease contexts.
Nascent efforts are underway to estab-
lish the feasibility of performing com-
prehensive tumor genetic profiling, in-
cluding deep sequencing, in clinical
trials. Large profiling efforts such as the
NCI’s proposed 1,000 patient MATCH
program seek to incorporate this informa-
tion into clinical decisionmaking (Sawyers
et al., 2013). A series of comparative
phase 2 studies would then compare
novel treatment approaches with stan-
dard therapies in well-defined patient
populations. The study design is neces-
sarily complex, and implementation is
expected to be challenging. However,
the potential reward in rapidly correlating
response with genomic information in
appropriate patient populations seems
compelling.
We believe that these profiling efforts
can and should be accelerated to maxi-
mize the potential utility of dozens of
targeted agents, both approved and in
development. As an initial step, we pro-
pose a minimum strategy of annotat-
ing routine pathologic information with
detailed sequence information from a
set of several hundred genes, including
cancer drivers and others with action-
able mutations. Such a data set has
the potential to address a number of
worthwhile objectives simultaneously.
First and most importantly, the unique
data generated would enable clinical
decision making for individual patients,
particularly those with advanced dis-
ease and limited options. Second,
the data would provide correlative
genetic information to evaluate the per-
formance of companion diagnostics.
Third, such an approach would provide
abundant opportunities for pilot studies
to address issues related to specimen
collection and processing, data quality,
data storage, reporting to cliniciansInc.and patients, data sharing for research,
and costs.
A key aspect of this proposed approach
is that it creates an opportunity to
leverage the value of genomic profiling
of individual patients by identifying and
collecting cases characterized by unusual
efficacy of a targeted agent, particularly
cases outside of approved treatment indi-
cations. In this way, emerging clinical
experience can be brought to bear on
the question of whether a given mutation
is likely to be a cancer driver in a particular
cancer type. Ongoing broad-based tumor
sequencing efforts can be leveraged as
well. For example, in 2011, BRAF V600E
mutations were identified in 48 out of 48
patients with classic hairy cell leukemia
(HCL) (Tiacci et al., 2011), a relatively
rare disease, and subsequent case re-
ports have documented responses to ve-
murafenib in refractory HCL (Dietrich
et al., 2012).
As illustrated by the experience with
BRAF V600Emutations in hairy cell leuke-
mia, a very small number of informative
cases could be sufficient to advance
clinical drug research in promising areas.
The result could be more focused and
parsimonious oncology drug develop-
ment accompanied, when necessary,
by limited changes in disease classifica-
tion to accommodate emerging informa-
tion. Sponsors and regulatory agencies
would rapidly gain information to allow
approval-seeking studies, information
that would be particularly valuable in
rare indications. Because the most infor-
mative responses typically occur in the
context of single-agent treatment, oncol-
ogists and others should be trained and
incentivized to report to regulatory
agencies unusually complete or durable
responses to single agents, particularly
those observed with a targeted agent in
the setting of otherwise refractory dis-
ease. More efficient reporting of well-an-
notated cases in the future, coupled with
clinical trial innovations, such as the flex-
ible and adaptable basket design, will
accelerate the routine practice of preci-
sion oncology.
We base the idea of ‘‘mining’’ emerging
clinical experience to capture unusual
responses in genomically annotated
cases on the established principles of
safety pharmacovigilance to detect un-
usual or infrequent toxicities, as currently
practiced by the FDA and other regulatory
agencies. Though various aspects of
pharmacovigilance have been criticized,
broad-based reporting of serious adverse
events, typically including a defined set
of clinical information, remains routine.
In many cases, adverse event reporting
has allowed prompt regulatory action to
protect public health (Crowther, 2013).
We believe that the availability of targeted
agents, together with relevant tumor-
derived genomic information, enhances
the opportunity for precision oncology,
and we look to regulatory agencies for
elaboration of ‘‘precision approval’’ paths
necessary to realize this vision. A key first
step is to create a simple system for effi-
cacy reporting with sufficient incentives
to ensure broad-based sampling of the
emerging clinical experience. Regulatory
authorities should enforce phase 4 com-
mitments as a condition of approval to
provide significant incentives (and oppor-
tunities) for the sponsor of a new drug.
An example would be a requirement for
drug sponsors to monitor off-label ex-
perience by providing genomic profiling
for treated patients and for collecting
essential follow up information. National
health systems and payers have obvious
incentives to direct the use of expensive
targeted agents to the patients most
likely to benefit.
That the pursuit of better treatment
for cancer patients will be greatly aided
by comprehensive genomic profiling
seems inarguable. Using this information
together with an ever-increasing arsenal
of rationally targeted agents will provide
unprecedented opportunities to match
the right patient with the right treatment,
ultimately improving outcomes for many.
But translation from genetic lesions to
effective cancer treatments has proven
that tissue contextmatters critically.More-
over, the relative contributions of the
genomic profile and the specific tissue
context to the clinical response are likely
to be drug specific and, to a large degree,
will need to be empirically determined
through rigorous clinical evaluation.
Omnibus attempts to reclassify cancers
across tissues according to their genetic
defects are premature. Given this reality,
continued efforts to refine clinical trial
designs to accommodate genomic and
epigenetic profiling represent a more
urgent need.ACKNOWLEDGMENTS
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